Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS Malignancies
2024

Combining CIK Cell Therapy with PPAR Ligands for Brain Cancer Treatment

publication Evidence: moderate

Author Information

Author(s): Kira Vordermark, JingJing Pu, Amit Sharma, Jarek Maciacyzk, Ingo G. H. Schmidt‐Wolf

Primary Institution: University Hospital of Bonn

Hypothesis

Can the combination of CIK cell therapy and PPARγ antagonists enhance treatment efficacy for neuroblastoma and glioblastoma?

Conclusion

The study suggests that combining PPAR ligands with CIK cell immunotherapy could be an effective treatment for malignant CNS tumors.

Supporting Evidence

  • CIK cell therapy has been successful in glioblastoma clinical trials.
  • PPARγ antagonists were shown to suppress tumor cell growth in neuroblastoma and glioblastoma.
  • Combining PPARγ inhibition with CIK cell therapy significantly enhanced cell lysis.

Takeaway

This study looks at how a special type of immune cell therapy can work better when paired with certain drugs for brain cancer.

Methodology

The study investigated neuroblastoma and glioblastoma cell lines with mature CIK cells and the PPARγ antagonist GW‐9662 to assess effects on cell viability and gene expression.

Limitations

Further confirmation in in vivo models is needed to validate findings.

Statistical Information

P-Value

p≤0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/cam4.70497

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication